
An AI app told me when I'd die — and I liked it
When a friend mentioned that he'd used a new artificial-intelligence-powered smartphone app called Death Clock AI to learn when his ticker would give out, I wanted to know my end date as well. I had used a rudimentary web-based calculator nearly a decade ago, which said my time would be up in 2031 — now just six years away! I was hoping an app combining AI and statistical modeling to predict my personal life expectancy would buy me more time.
It did! I am pleased to report that I won't die until 2042, at age 84.
Those early death clocks — or longevity calculators — used only basic information to estimate how much time you had left. (The web-based tool I used previously asked four questions — about birth date, body mass index, smoking and mental health status.) There are, of course, other life expectancy calculators — the Social Security Administration provides one, as do such insurance companies as John Hancock and Northwest Mutual. But Death Clock AI is a giant step ahead with its reliance on artificial intelligence, which is fed by user data and trained on more than 1,200 life expectancy studies, allowing for a more personalized prediction of a death date.
As such, the app highlights both the promise and the perils of AI.
Although the specific date of death is obviously not intended to be accurate — the app's disclaimer says it's 'for fun only' — it does tie your personal habits to your likelihood of living into old age and tells you what lifestyle changes might buy you more time. Thus Death Clock AI's motto: 'Know your date. Change your fate.'
After responding to 29 questions — including how much of the day I spend sitting, whether I get at least seven hours of sleep a night and whether I get all my recommended cancer screenings — I had my answer. A darkly humorous 'Save the Date' card suggested I plan my end-of-life celebration for April 17, 2042, but I also learned the most likely ways I would die: sleep disorders, cardiovascular disease or cancer, in that order. Of course, cancer and heart disease are the two big killers in the United States. But I was surprised by how harmful sleep issues are.
I was glad to get 17 more years instead of the measly six, even though I knew the Save the Date stuff is just marketing. Company founder and CEO Brent Franson is candid about the app's real value, which is providing a better understanding of how lifestyle changes can affect our longevity.
For instance, I saw that if I ate more fruits and vegetables, slept better and exercised more, I could extend my life expectancy an additional five years for a total of 22. (It's a whole other question as to whether I'd want to live into my 90s, recalling my mother's complaint that to be among the last of her friends and family living is no fun.) Taking up smoking or eating more fast food would mean I'd be planning an earlier farewell.
But don't we already know that smoking is bad and that exercise and broccoli are good? Yes, but seeing your own possible expiration date is a powerful in-your-face message that shows you the effect of your habits.
I asked Franson, 42, what his own quiz had told him. He learned that he'd die at age 78, which is about the usual life expectancy of a White male in the United States. On the one hand, he said, 'I consider myself pretty healthy. I'm 42 and pretty active. I think I eat pretty well. I mostly don't drink.' But, he added, his A1C, a test that shows the average blood sugar level over the past two to three months, is 'a bit high' and his cholesterol number and blood pressure are also problematically high, suggesting that his heart health could be a concern going forward. The app, he said, 'is making me aware of this in no uncertain terms. … I've got to take that really seriously.'
I had a similar reaction. I know how poorly I sleep, and I know how important a good night's sleep is. But when my results showed I'm most likely to die because of a sleep disorder, I had an 'aha' moment. Knowing that improving my sleep would remove my top death threat just might motivate me to do something about it, such as keeping to a regular schedule, avoiding large meals before bedtime, getting rid of screens in my bedroom and limiting naps.
I asked Arthur Caplan, a bioethicist at NYU, for his opinion on the Death Clock AI. Caplan, 75, told me the app predicted he has 14 more years. But he cautioned that many other factors also influence lifespan, including our genes, which help determine our risk for certain diseases.
In fact, Caplan said, 'the majority of your lifespan is driven by your parents' income, your educational level, whether you have a job, whether you live downstream from polluting chemical refineries or a radioactive plant that's dumping something into your water.' Most of these factors are impossible to alter, so the app doesn't ask about them. The point, Franson said, is 'to ask about things that people can change.'
Other experts agree that there are concerns about an app offering up a death date, including harmful effects on mental health and financial planning.
Ryan Zabrowski, a financial planner, said: 'One of the greatest concerns for retirees is the risk of outliving their money. A tool like a Death Clock AI could empower people to make smarter, more informed financial decisions.' Unless, of course, the prediction is wrong.
Still, getting a reminder that we have some control over our health in a way that may affect longevity is important.
Experts caution that anyone entering personal data into an app should be careful. The final, optional step in the Death Clock AI app is a free trial of its Longevity Plan ($39 a year), which will allow you to upload lots of your personal health data for customized help. But the app's privacy policy says the information you provide could be shared with business partners (security consultants, analytics providers, payment processors) and with advertisers, marketers and data brokers.
Franson says his company is not selling the data and is instead focused on the subscription business model. He added, 'I think ultimately the business model needs to evolve because some people don't like paying for subscriptions,' suggesting the company might develop partnerships to market such recommended products as vitamins or sleep trackers, which is a common practice. Still, when it comes to privacy, the devil can be in the details. The company's privacy policy reads in part:
'All of your Personal Data that we collect may be transferred to a third party if we undergo a merger, acquisition, bankruptcy … in which that third party assumes control of our business (in whole or part).' So buyer beware.
As I was finishing up this column, I was curious what the Social Security Administration's tool, which uses two questions (age and sex), would say about my life expectancy. It was basically the same as Death Clock AI — I've got 17 years left. But who really knows.
I'll try to live with no regrets, as though each day could be my last.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Crayon expands Google Cloud partnership to include mid-market distribution, focused on AI innovation
OSLO, Norway, June 10, 2025 /PRNewswire/ -- Crayon, a global leader in IT services and innovation, announced a significant expansion of its strategic partnership with Google Cloud. This enhanced partnership will empower Crayon's extensive channel network to deliver Google Cloud's artificial intelligence (AI) technologies and cloud solutions more effectively to businesses worldwide by enabling Crayon's distribution capabilities across more market segments. As a Google Cloud Distributor, Crayon is crucial in enabling its broad network of resellers and channel partners, now including those who operate in the mid-market segment. This includes providing streamlined access to Google Cloud's portfolio, offering specialized support and enablement programs, and simplifying billing and management, with a strong emphasis on accelerating the adoption of Google Cloud's leading AI capabilities. "This expanded partnership with Google Cloud is a landmark achievement for Crayon and our partners," said Crayon CEO Melissa Mulholland. "Our strength lies in our extensive channel network, reaching hundreds of thousands of end-customers. As a Google Cloud Distributor, we can now equip our partners more effectively with the premier AI and cloud technologies from Google Cloud, enabling them to drive innovation and deliver exceptional value to their clients." Through closer collaboration with Google Cloud, Crayon aims to make powerful AI tools and infrastructure more accessible to organizations of all sizes, helping them innovate faster and harness the full potential of AI. "Crayon possesses a deep understanding of the channel and a vast ecosystem of partners skilled in cloud and AI solution delivery," said Kevin Ichhpurani, President, Global Partner Ecosystem at Google Cloud. "By continuing to elevate our partnership, Crayon and Google Cloud are helping companies of all types and sizes benefit from leading AI and trusted global cloud infrastructure." This collaboration underscores both companies' commitment to fostering innovation through the channel and empowering businesses with the cloud and AI technologies needed to thrive. CONTACT: For more information contact: Astrid Mannion-Gibson Global Senior Communications Manager, Crayon Phone: +47 466 32 010 Email: This information was brought to you by Cision View original content: SOURCE Crayon


Bloomberg
14 minutes ago
- Bloomberg
Mark Zuckerberg Personally Hiring to Create New 'Superintelligence' AI Team
Mark Zuckerberg, frustrated with Meta Platforms Inc. 's shortfalls in AI, is assembling a team of experts to achieve artificial general intelligence, recruiting from a brain trust of AI researchers and engineers who've met with him in recent weeks at his homes in Lake Tahoe and Palo Alto. Zuckerberg has prioritized recruiting for the secretive new team, referred to internally as a superintelligence group, according to people familiar with his plans. He has an audacious goal in mind, these people said. In his view, Meta can and should outstrip other tech companies in achieving what's known as artificial general intelligence or AGI, the notion that machines can perform as well as humans at many tasks. Once Meta reaches that milestone, it could weave the capability into its suite of products — not just social media and communications platforms, but also a range of AI tools, including the Meta chatbot and its AI-powered Ray-Ban glasses.


Medscape
22 minutes ago
- Medscape
CVD Mortality Higher in Women With Inflammatory Diseases
Although cardiovascular disease (CVD)-related mortality decreased significantly from 1999 to 2020 in both men and women with immune-mediated inflammatory diseases (IMIDs), women consistently had higher rates of CVD-related mortality than men over the 22-year period. METHODOLOGY: Researchers analyzed CDC Multiple Cause of Death files from 1999 to 2020 to assess the sex differences in CVD-related mortality in patients with IMIDs. They identified CVD-related deaths with underlying IMIDs in the United States using diagnostic codes. IMIDs such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis were analyzed. The analysis included 281,355 IMID-related deaths and 127,149 CVD-related deaths over a period of 22 years. Annual crude and adjusted death rates were estimated. TAKEAWAY: Age-adjusted CVD-related mortality for women with IMIDs declined from 3.3 per 100,000 in 1999 to 1.4 per 100,000 in 2020, whereas the rate in men with IMIDs declined from 2.3 to 1.1 per 100,000 ( P < .01). < .01). However, women had higher mortality than men throughout the study duration (mortality rate ratio, 1.5; P < .01). < .01). Cerebrovascular disease and ischemic heart disease were major causes of death, with women more affected than men; women experienced mortality from arrhythmia and cardiac arrest at more than twice the rate of men. Among patients with IMIDs, women with rheumatoid arthritis had disproportionately higher crude CVD-related mortality than men with rheumatoid arthritis. IN PRACTICE: 'Addressing these risks requires increasing awareness of atypical cardiovascular symptoms in females with IMIDs, enhancing early detection through advanced imaging, and ensuring equitable access to therapies like biologics,' the study authors wrote. SOURCE: This study was led by Issam Motairek, MD, Cleveland Clinic, Cleveland. It was published online on May 5, 2025, in Circulation: Cardiovascular Quality and Outcomes . LIMITATIONS: The potential inaccuracies in the codes for identifying the cause of death may have misclassified IMIDs or CVD-related causes. The aggregate data structure prevented the analyses of individual-level factors such as severity of disease or treatments. Less common IMIDs were excluded, which may have underestimated their contribution to CVD. DISCLOSURES: This study received no specific funding. The authors reported having no conflicts of interest.